Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy

doi:10.1016/S0304-3940(99)00450-4

Neuroscience Letters

Volume 270, Issue 1, 23 July 1999, Pages 25-28

https://doi.org/10.1016/S0304-3940(99)00450-4 Get rights and content

Abstract

We investigated whether interleukin-1 (IL-1), a mediator of inflammatory pain, also plays a role in pain induced by nerve injury. Female C57BL/6-mice with a chronic constrictive injury of one sciatic nerve, an established model of neurogenic hyperalgesia and allodynia, were treated with different doses (10–80 μg) of a neutralizing monoclonal rat antibody to IL-1 receptor I (anti-IL-1RI). This antibody dose-dependently reduced thermal hyperalgesia and mechanical allodynia in the animals. Furthermore, immunoreactivity for the proinflammatory cytokine tumor necrosis factor-α (TNF) was reduced in mice treated with the highest dose of anti-IL-1RI. Degeneration of myelinated fibers was not altered by any of the treatment schedules. We conclude that IL-1 may be a mediator of hyperalgesia after nerve lesion.

Section snippets

Acknowledgements

We would like to thank B. Dekant and L. Biko for technical assistance. This work was supported by Deutsche Forschungsgemeinschaft So 328/2–1 and SFB 353. Presented in part at the Meeting of the Society for Neuroscience, Nov 10, 1998.

References (23)

G.J. Bennett et al.
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Pain
(1988)
S.R. Chaplan et al.
Quantitative assessment of tactile allodynia in the rat paw
J. Neurosci. Methods
(1994)
M.J. Elliott et al.
Anti-cytokine therapy in rheumatoid arthritis
Baillieres Clin. Rheumatol.
(1995)
H. Fukuoka et al.
Cutaneous hyperalgesia induced by peripheral injection of interleukin-1β in the rat
Brain Res.
(1994)
K. Hargreaves et al.
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Pain
(1988)
N.J. Rothwell et al.
Cytokines in neurodegeneration and repair
Int. J. Dev. Neurosci.
(1995)
S. Rotshenker et al.
Interleukin-1 activity in lesioned peripheral nerve
J. Neuroimmunol.
(1992)
C. Sommer et al.
Painful mononeuropathy in C57BL/Wld mice with delayed Wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivity
Brain Res.
(1998)
C. Sommer et al.
Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1
Exp. Neurol.
(1998)
L.S. Sorkin et al.
Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres
Neuroscience
(1997)

M. Wells et al.

Changes in plasma cytokines associated with peripheral nerve injury

J. Neuroimmunol.

(1992)

Cited by (172)

Neuroinflammation: Breaking barriers and bridging gaps
2023, Neuroscience Research
Neurons are the cells of the nervous system and are responsible for every thought, movement and perception. Immune cells are the cells of the immune system, constantly protecting from foreign pathogens. Understanding the interaction between the two systems is especially important in disease states such as autoimmune or neurodegenerative disease. Unfortunately, this interaction is typically detrimental to the host. However, recent efforts have focused on how neurons and immune cells interact, either directly or indirectly, following traumatic injury to the nervous system. The outcome of this interaction can be beneficial – leading to successful neural repair, or detrimental – leading to functional deficits, depending on where the injury occurs. This review will discuss our understanding of neuron-immune cell interactions after traumatic injury to both the peripheral and central nervous system.
A randomized, placebo-controlled, double-blinded mechanistic clinical trial using endotoxin to evaluate the relationship between insomnia, inflammation, and affective disturbance on pain in older adults: A protocol for the sleep and Healthy Aging Research for pain (SHARE-P) study
2023, Brain, Behavior, and Immunity - Health
Chronic pain is prevalent in older adults. Treatment, especially with opioids, is often ineffective and poses considerable negative consequences in this population. To improve treatment, it is important to understand why older adults are at a heightened risk for developing chronic pain. Insomnia is a major modifiable risk factor for chronic pain that is ubiquitous among older adults. Insomnia can also lead to heightened systemic inflammation and affective disturbance, both of which may further exacerbate pain conditions in older adults. Endotoxin exposure can be used as an experimental model of systemic inflammation and affective disturbance. The current study aims to understand how insomnia status and endotoxin-induced changes in inflammation and affect (increased negative affect and decreased positive affect) may interact to impact pain facilitatory and inhibitory processes in older adults. Longitudinal data will also assess how pain processing, affective, and inflammatory responses to endotoxin may predict the development of pain and/or depressive symptoms. The current study is a randomized, double-blinded, placebo-controlled, mechanistic clinical trial in men and women, with and without insomnia, aged 50 years and older. Participants were randomized to either 0.8ng/kg endotoxin injection or saline placebo injection. Daily diaries were used to collect variables related to sleep, mood, and pain at two-week intervals during baseline and 3-, 6-, 9-, and 12-months post-injection. Primary outcomes during the experimental phase include conditioned pain modulation, temporal summation, and affective pain modulation ∼5.5 hours after injection. Primary outcomes for longitudinal assessments are self-reported pain intensity and depressive symptoms. The current study uses endotoxin as an experimental model for pain. In doing so, it aims to extend the current literature by: (1) including older adults, (2) investigating insomnia as a potential risk factor for chronic pain, (3) evaluating the role of endotoxin-induced affective disturbances on pain sensitivity, and (4) assessing sex differences in endotoxin-induced hyperalgesia.
NCT03256760.
NIH R01AG057750-01.
Are sensory neurons exquisitely sensitive to interleukin 1β?
2021, Journal of Neuroimmunology
Peripheral nerve injury frequently evokes chronic neuropathic pain. This is initiated by a transient inflammatory response that leads to persistent excitation of dorsal root ganglion (DRG) neurons by inflammatory cytokines such as interleukin 1β(IL-1β). In non-neuronal cells such as lymphocytes, interleukin 1 exerts actions at attomolar (aM; 10⁻¹⁸ M) concentrations. We now report that DRG neurons in defined-medium, neuron-enriched culture display increased excitability following 5–6 d exposure of 1aM IL-1β. This response is mediated in part by type 1 interleukin receptors and involves decreased function of putative K_Ca1.1 channels. This finding provides new insights into the neuroimmune interactions responsible for neuropathic pain.
Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia
2020, European Journal of Pharmaceutical Sciences
Toll-like receptor 4 (TLR4) recognizes various endogenous and microbial ligands and is an essential part in the innate immune system. TLR4 signaling initiates transcription factor NF-κB and production of proinflammatory cytokines. TLR4 contributes to the development or progression of various diseases including stroke, neuropathic pain, multiple sclerosis, rheumatoid arthritis and cancer, and better therapeutics are currently sought for these conditions. In this study, a library of 140 000 compounds was virtually screened and a resulting hit-list of 1000 compounds was tested using a cellular reporter system. The topoisomerase II inhibitor mitoxantrone and its analogues pixantrone and mitoxantrone (2-hydroxyethyl)piperazine were identified as inhibitors of TLR4 and NF-κB activation. Mitoxantrone was shown to bind directly to the TLR4, and pixantrone and mitoxantrone (2-hydroxyethyl)piperazine were shown to inhibit the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNFα) in primary microglia. The inhibitory effect on NF-κB activation or on TNFα production was not mediated through cytotoxity at ≤ 1 µM concentration for pixantrone and mitoxantrone (2-hydroxyethyl)piperazine treated cells, as assessed by ATP counts. This study thus identifies a new mechanism of action for mitoxantrone, pixantrone, and mitoxantrone (2-hydroxyethyl)piperazine through the TLR4.
Central IRAK-4 kinase inhibition for the treatment of pain following nerve injury in rats
2020, Brain, Behavior, and Immunity
There is ample evidence for the role of the immune system in developing chronic pain following peripheral nerve injury. Especially Toll-like receptors (TLRs) and their associated signaling components and pro-inflammatory cytokines such as IL-1β, induced after injury, are involved in nociceptive processes and believed to contribute to the manifestation of chronic neuropathic pain states. Whereas the inhibition of the kinase function of IRAK-4, a central kinase downstream of TLRs and IL-1 receptors (IL-1Rs), seems efficacious in various chronic inflammatory and autoimmune models, it’s role in regulating chronic neuropathic pain remained elusive to date. Here, we examined whether pharmacological inhibition of IRAK-4 kinase activity using PF-06650833 and BMS-986147, two clinical-stage kinase inhibitors, is effective for controlling persistent pain following nerve injury. Both inhibitors potently inhibited TLR-triggered cytokine release in human peripheral blood mononuclear cell (PBMC) as well as human and rat whole blood cultures. BMS-986147 showing favorable pharmacokinetic (PK) properties, significantly inhibited R848-triggered plasma TNF levels in a rat in vivo cytokine release model after single oral dosing. However, BMS-986147 dose dependently reversed cold allodynia in a rat chronic constriction injury (CCI) model following intrathecal administration only, supporting the notion that central neuro-immune modulation is beneficial for treating chronic neuropathic pain. Although both inhibitors were efficacious in inhibiting IL-1β- or TLR-triggered cytokine release in rat dorsal root ganglion cultures, only partial efficacy was reached in IL-1β-stimulated human glial cultures indicating that inhibiting IRAK-4́’s kinase function might be partially dispensable for human IL-1β driven neuroinflammation. Overall, our data demonstrate that IRAK-4 inhibitors could provide therapeutic benefit in chronic pain following nerve injury, and the central driver for efficacy in the neuropathic pain model as well as potential side effects of centrally available IRAK-4 inhibitors warrant further investigation to develop effective analgesia for patients in high unmet medical need.
Long-term actions of interleukin-1β on K + , Na + and Ca 2+ channel currents in small, IB <inf>4</inf> -positive dorsal root ganglion neurons; possible relevance to the etiology of neuropathic pain
2019, Journal of Neuroimmunology
Excitation of dorsal root ganglion (DRG) neurons by interleukin 1β (IL-1β) is implicated in the onset of neuropathic pain. To understand its mechanism of action, isolectin B4 positive (IB₄⁺) DRG neurons were exposed to 100pM IL-1β for 5-6d. A reversible increase in action potential (AP) amplitude reflected increased TTX-sensitive sodium current (TTX-S I_Na). An irreversible increase in AP duration reflected decreased Ca²⁺- sensitive K⁺ conductance (BK(Ca) channels). Different processes thus underlie regulation of the two channel types. Since changes in AP shape facilitated Ca²⁺ influx, this explains how IL-1β facilitates synaptic transmission in the dorsal horn; thereby provoking pain.

View all citing articles on Scopus

View full text

Article preview

Neuroscience Letters

Abstract

Section snippets

Acknowledgements

References (23)

A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man

Pain

Quantitative assessment of tactile allodynia in the rat paw

J. Neurosci. Methods

Anti-cytokine therapy in rheumatoid arthritis

Baillieres Clin. Rheumatol.

Cutaneous hyperalgesia induced by peripheral injection of interleukin-1β in the rat

Brain Res.

A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia

Pain

Cytokines in neurodegeneration and repair

Int. J. Dev. Neurosci.

Interleukin-1 activity in lesioned peripheral nerve

J. Neuroimmunol.

Painful mononeuropathy in C57BL/Wld mice with delayed Wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivity

Brain Res.

Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1

Exp. Neurol.

Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres

Neuroscience

Changes in plasma cytokines associated with peripheral nerve injury

J. Neuroimmunol.

Cited by (172)

Neuroinflammation: Breaking barriers and bridging gaps

A randomized, placebo-controlled, double-blinded mechanistic clinical trial using endotoxin to evaluate the relationship between insomnia, inflammation, and affective disturbance on pain in older adults: A protocol for the sleep and Healthy Aging Research for pain (SHARE-P) study

Are sensory neurons exquisitely sensitive to interleukin 1β?

Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia

Central IRAK-4 kinase inhibition for the treatment of pain following nerve injury in rats

Long-term actions of interleukin-1β on K <sup>+</sup> , Na <sup>+</sup> and Ca <sup>2+</sup> channel currents in small, IB <inf>4</inf> -positive dorsal root ganglion neurons; possible relevance to the etiology of neuropathic pain